.jpeg?crop=yes&w=340&h=340&itok=AkyLpAAZ "obesity scan person"){kind=icon}
Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...
-
ICON announces results of annual general meeting
ICON plc today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders.
-
ICON reports second quarter 2025 results
ICON plc today reported its financial results for the second quarter ended June 30, 2025.
-
ICON’s leadership and performance in phase 1 clinical trials recognised in independent industry benchmarking report
ICON plc has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR).
-
ICON and its employees recognised as clinical research industry leaders, and for innovation and progress in sustainability
ICON was also recognised as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards.
-
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
ICON plc today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025.
-
ICON releases its ICON Cares 2024 Report
The report outlines how the company is delivering on its environmental, social and governance (ESG) goals, as delivered through its ICON Cares program.
-
.jpeg?crop=yes&w=545&h=545&itok=DO7b0zOn "obesity scan person")
Global ICON survey shows need for more efficient obesity clinical trial design
ICON plc today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
ICON report first quarter 2025 results
Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue.
-
Mural Health and ICON announce partnership
Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, Mural Link.
-
ICON reports fourth quarter and full year 2024 results
Full year net business wins of $9,974 million; a net book to bill of 1.20.
